3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Sarcoma
4
Sarcoma, Ewing
3
Osteosarcoma
3
Liposarcoma
3
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Neuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Breast Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Colonic Neoplasms
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Acquired Immunodeficiency Syndrome
1
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
abemaciclib
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled